TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Consumption of analgesic Level III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-lead ECG data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in average percent of oil by volume in the porridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of global life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Discrimination capacity of the study model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sialometry measurements of xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal well-being
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal well-being
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial Attentional Resource Allocation Task reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial Attentional Resource Allocation Task omission errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rapid Visual Information Processing Task hit rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rapid Visual Information Processing Task reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Detection Task accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Detection reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HbA1c less than 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to first episode of syncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ropivacaine Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of parietal invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of metabolic dysfunction-associated steatohepatitis (MASH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of Less Than or Equal to 6 Eosinophils/High Power Field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Virologic Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grades of study product-related solicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of infection with RSV
Endpoint domain: Adverse events/effects
Primary endpoint: SinoNasal Outcome Test (SNOT 22)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breastfeeding attitude with Iowa Infant Feeding Attitude Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Subjects With Anti-rabies Antibody Titer of ≥0.5 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Five-year survival of patients
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Subjects With ≥1-Point Improvement on the Lip Fullness Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac output estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Toxicity of multiple peptide vaccinations
Endpoint domain: Adverse events/effects
Primary endpoint: Memory loss mechanisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA Less Than 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility of rTMS delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tolerance of rTMS
Endpoint domain: Adverse events/effects
Primary endpoint: Early evaluation of cardiac amyloidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vector's parous rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to First Confirmed Clinical Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Intestinal integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time-matched QTcI Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Peak Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overlapping Days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Opioid Days
Endpoint domain: Adverse events/effects
Primary endpoint: Benzodiazepine Days
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Cancer Screening Tests Completed - Intention to Treat
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Cancer Screening Tests Completed - As Treated
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cardiac symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of life (QOS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in brain microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in brain plasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tinnitus Inventory Handicap scoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Five-Year Survivorship
Endpoint domain: Mortality/survival
Primary endpoint: Changes in visual field functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Freedom from any failure
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Elevated Venous Lactate Levels More Than 2 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tolerability to Complete the Entire 20 Week Study on Study Drug
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: On-Therapy Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Osteoarthritis Quality Indicator
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the Bent Knee Fall Out test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase II dose
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Safety profile
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Change of systolic mitral valve annular velocity (S')
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Ménière's Vertigo Attack Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Re-stenosis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative Complete Haematological Response (CHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative Complete Cytogenetic Response (CCyR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative Major Molecular Response (MMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Patients With Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants without infusional toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of PCA morphine used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduce severity of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reduced stool volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in National Institutes of Health Stroke Scale (NIHSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in modified Barthel Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in modified Rankin Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Glasgow coma scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MRI evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of insulinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Correlation between BJHS and Wheezing/Asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Front Surface Lens Deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brief Pain Inventory-Short Form Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean area under the curve of pain intensity scores with activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Related Quality of Life (HR-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean hemoglobin level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: major haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes of serum malondialdehyde
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Interleukin-1β levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: tumor necrotic factor-α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: nitric oxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful initiation of lactation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive ventilation or death
Endpoint domain: Mortality/survival
Primary endpoint: Change in Frequency of Cellphone Unlocks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Jaw contour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anal Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall Intracranial Response Rate (OIRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disease burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient State Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Primary screening participation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Carotid artery reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Perceived health index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Perceived health scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: antiretroviral (ART) adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: longest lasting protection against Meningococcal C disease
Endpoint domain: Mortality/survival
Primary endpoint: Target Gene Expressions in Osteoarthritic Knee Cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Global rating of improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intravascular incidence
Endpoint domain: Adverse events/effects
Primary endpoint: lercanidipine concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geriatric anxiety scale (GAS-10)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geriatric depression scale (GDS-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Collett Lester Fear of Death scale (CL-FOD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CTP-543 metabolites and exposure in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of SpO2 < 80%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Spontaneous ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of paliperidone palmitate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Observed Plasma Concentration (Tmax) of paliperidone palmitate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of paliperidone palmitate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of obtained biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ostomy adjustment scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Healing of rickets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Acylcarnitine/Carnitine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in ETDRS Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anxiety Severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amount of bone height gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in serum vitamin B12 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in serum vitamin B1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in serum vitamin B6 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of 30-day primary fascial closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hepatic vein and right atrium pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perceived usefulness of the Med-alert Device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Young Mania Rating Scale (Y-MRS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Remicade Injection (Infliximab)
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in GLP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Difference in glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Scapular Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Radiation Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Delayed Radiation Complications
Endpoint domain: Adverse events/effects
Primary endpoint: discharge serum creatinine (SCr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: frequencies of use of SSR templates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Disease-free Survival at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Tumour blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tumour metabolic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Local Reactions Within 7 Days After Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Systemic Events Within 7 Days After Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 6 Months Following Dose 4
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of procedure or implant related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Six-minute Walk Distance Test (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skin texture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Endothelial lesion-repair biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in dopamine transporter occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Heat Pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cold Pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cold Pain Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation Satisfaction in Social Roles and Activities
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Participation Ability in Social Roles and Activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Work Productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cumulative Narcotic Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in CDRS-R Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recommended Dose (RD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Improvement of Restless Legs Symptoms (IRLS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective Improvement of Restless Legs Symptoms (KRLS QOL)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective Improvement of Restless Legs Symptoms (MSI Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion after HRV vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cerebro-splanchnic oxygenation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the curve (AUC) of plasma concentration vs. time of total curcumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of total curcumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum plasma concentration (Tmax) of total curcumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma anti-factor Xa level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in coronary flow reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Steroid-free remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: angiographic efficacy measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Absolute Change in Acne Lesion Counts (Inflammatory)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Absolute Change in Acne Lesion Counts (Non-inflammatory)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Subjects Who Achieved ≥ 2-grade Improvement in the Investigator Global Assessment of Acne (IGA)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score (KOOS) Sport/Rec Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Laboratory assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes